hypocalcemia
HYPOCALCEMIA
Hypocalcemia is the occurs when serum calcium concentration is below the lower limit of normal range.
Acute hypocalcemia has neuromuscular tetany as hallmark symptom. Patients have rapid decrease in serum calcium and present with symptomatic hypocalcemia.
It is an emergency condition and requires immediate attention. Ca (IV) should be administered until signs and symptoms abate or until serum Ca levels rise.
Chronic hypocalcemia has asymptomatic mild hypocalcemia. Treatment is necessary to avoid long term complications. Oral Ca may be administered.

Principles of Therapy

  • Treatment will depend on the severity, cause, presence of symptoms & how rapidly the hypocalcemia developed
Acute Hypocalcemia
  • Emergency which requires immediate attention
  •  Ca (IV) should be administered until signs & symptoms abate or until serum Ca levels rise
Chronic Hypocalcemia
  • Treatment is necessary to avoid long term complications
  • Ca (oral) may be administered

Pharmacotherapy

Ca (PO or IV)
  • Patients who present w/ signs & symptoms of acute hypocalcemia need to be treated w/ rapid parenteral administration of Ca
  • Different salts are available for IV administration
  • Chronic, asymptomatic hypocalcemia may be treated w/ Ca (PO)
Mg (PO or IV)
  • Administer Mg (IV) if acute hypocalcemia is associated w/ hypomagnesemia
  • As soon as possible administer Mg (PO) to replace body stores since Mg (IV) is excreted in the urine
  • Specific prescribing information may be found in the latest MIMS & the Hypomagnesemia Management Chart
Vit D Analogs (PO or IV)
  • May be necessary in cases of Vit D deficiency or resistance, dialysis patients, hypocalcemia from subtotal parathyroidectomy
  • Analogue of Vit D to be administered will depend on underlying disorder
  • If renal 1-α-hydroxylation is impaired (eg renal failure, hypoparathyroidism, etc):
    • Administer metabolites that do not require this modification
    • Calcitriol or Dihydrotachysterol
  • If decreased intake or increased losses:
    • Administer Vit D & treat underlying disorder
  • Alfacalcidol is one of the preferred agents in chronic renal failure (CRF) because it does not require renal hydroxylation
    • May also be used in hypoparathyroidism, Vit D-resistant rickets, osteomalacia, pseudohypoparathyroidism, malabsorption of Ca
  • Calcifediol is one of the preferred agents to treat simple nutritional deficiencies
    • May also be used to treat bone diseases associated w/ CRF or hypocalcemia caused by chronic renal dialysis
  • Calcitriol is one of the preferred agents in CRF particularly those undergoing dialysis because it does not require renal hydroxylation
    • May also be used to treat hypocalcemia caused by hypoparathyroidism, pseudohypoparathyroidism, Vit D-dependent & independent ricket
  • Cholecalciferol is used to treat simple nutritional deficiencies
  • Dihydrotachysterol is used to treat hypocalcemic tetany due to hypoparathyroidism & to treat hypocalcemia due to hypoparathyroidism
  • Ergocalciferol is used to treat simple nutritional deficiencies, Vit D- resistant rickets, hypoparathyroidism
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.